Lakefront Biotherapeutics (LKFT) Current Leases (2015 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Current Leases for 11 consecutive years, with $1.8 million the latest figure, recorded in Q1 2026.

• Quarterly Current Leases fell 48.42% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 48.42% YoY) and the FY2025 annual result came in at $2.0 million, down 50.3% from the prior year.
• Current Leases eased to $1.8 million in Q1 2026 per LKFT's latest filing, from $2.0 million in the prior quarter.
• Over the last five years, Current Leases for LKFT reached as high as $8.2 million in Q4 2022 and fell as low as $1.8 million in Q1 2026.
• A 5-year average of $4.6 million and a median of $4.7 million in 2024 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2022 — Current Leases climbed 0.07% — and 2025, when it tumbled 58.86%.
• Year by year, Current Leases stood at $8.2 million in 2022, then slumped by 35.47% to $5.3 million in 2023, then dropped by 25.21% to $4.0 million in 2024, then sank by 50.3% to $2.0 million in 2025, then declined by 8.39% to $1.8 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $1.8 million, $2.0 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.